Key Takeaways Medical guidance is essential GLP-1s should be prescribed and monitored by healthcare professionals as part of a holistic treatment plan
Retatrutide activates GIPR and GCGR , achieving over 20% weight loss in phase 2 trials
10.15386/mpr-2821 71 MischleyL
Shoaei-Hagh P, Kamelan Kafi F, Najafi S, Zamanzadeh M, Heidari Bakavoli A, Ramezani J, et al
In a phase 2 trial, cagrilintide led to greater weight reductions compared to placebo and liraglutide, with the highest dose achieving a mean weight reduction of 10.8% 1
Tesamorelin has two Phase III lipodystrophy trials (LIPO-010 and CTR-1011), pooled analyses across 816 participants, the Stanley 2019 Lancet HIV NAFLD trial, the Stanley 2014 JAMA abdominal-fat trial, and mechanistic transcriptomic and proteomic follow-up papers